This study evaluated stool-based DNA (sDNA) in 82 patients with colorectal cancer and 363 colonoscopically normal individuals using Exact’s version 2 technology. The study results were statistically consistent with the interim results and demonstrated 83% sensitivity for detecting cancers with a specificity of 82%. The interim study results from the first 40 cancer patients and 122 normal individuals reported 88% sDNA sensitivity for detecting cancer with a specificity of 82%.
Jeffrey Luber, president of Exact Sciences, said: “We are excited that these results are within the sensitivity range that was expected and we believe that they provide important validation of our version 2 technology.”